Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Keyphrases
Inter-laboratory Variation
100%
Programmed Death-ligand 1 (PD-L1)
100%
Netherlands
100%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
50%
Assay Reliability
50%
Digital Image Analysis
50%
Metastasis
50%
Primary Breast Cancer
50%
Human Epidermal Growth Factor Receptor 2 (HER2)
50%
Immunohistochemical Tests
50%
National Practice
50%
Practice Variation
50%
Biomarker Assessment
50%
Triple-negative Breast Cancer
50%
Positivity Rate
27%
Primary Tumor
21%
DG44
19%
Combined Positive Score
18%
Positivity Rate
15%
Abnormal Blood Glucose
12%
Dutch
12%
Combined Positive Score
11%
Test Characteristics
9%
Pathology Report
8%
Funnel Plot
8%
Ultra-low
7%
Tumor
7%
Patients with Breast Cancer
5%
Trastuzumab Deruxtecan (T-DXd)
5%
Medicine and Dentistry
Programmed Death 1 Ligand 1
100%
Head and Neck Squamous Cell Carcinoma
65%
Neck
62%
Evaluation Study
50%
Programmed Cell Death
50%
Newborn Morbidity
50%
Artificial Respiration
50%
Childbirth
50%
Patent Ductus Arteriosus
50%
Squamous Cell Carcinoma
50%
Triple Negative Breast Cancer
50%
Antidiabetic Agent
33%
Pembrolizumab
25%
Tissue Microarray
25%
Neoplasm
20%
Blood Glucose
16%
Prospective Cohort Study
16%
Respiratory Failure
16%
Pathologist
12%
Diagnostic Test
12%
Aortic Aneurysm Endovascular Graft
12%
Case Mix
9%
Funnel Plot
8%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
50%
Newborn Morbidity
50%
Patent Ductus Arteriosus
50%
Programmed Cell Death
50%
Head and Neck Squamous Cell Carcinoma
50%
Head and Neck Cancer
50%
Antidiabetic Agent
33%
Pembrolizumab
25%
Prospective Cohort Study
16%
Breast Cancer
16%
Respiratory Failure
16%
Neoplasm
12%
Malignant Neoplasm
8%
Immunotherapy
8%
